A Phase 2/3 interventional study of sildosin 4mg and dapoxetine 60mg in Premature (Early) Ejaculation, sponsored by Benha University. Completed at 1 site in Egypt. Open to male participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-23.
Sponsored by Benha University · Phase 2/3, Interventional, and Treatment
Both Silodosin 4 mg and Dapoxetine 60 mg significantly improved IELT and sexual function scores in primary PE patients. However, Silodosin exhibited a more favorable tolerability profile with fewer side effects, making it a safer, clinically effective alternative.
Dapoxetine 60 mg, the initial FDA-approved on-demand treatment for PE, which is a selective serotonin reuptake inhibitor (SSRI) . However, Silodosin 4 mg, an α1-adrenoceptor antagonist, has emerged as a promising alternative, particularly for patients dissatisfied with Dapoxetine . This investigation is designed to evaluate the efficacy and tolerability of Silodosin 4mg and Dapoxetine 60mg in the treatment of primary premature ejaculation.
2,550 studies on the registry are indexed under Premature Birth; 500 are open to participants now.
This study's enrollment of 95 is above the median of 84 across 1,666 interventional studies indexed under Premature Birth.
Browse Premature Birth studies →Benha University is the lead sponsor of 362 studies on the registry; 66 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
sildosin 4mg
Drug: sildosin 4mg
dapoxetine 60mg
Drug: dapoxetine 60mg
ondemand sildosin 4mg
ondemand dapoxetine 60mg
Intravaginal ejaculatory Latency time
changes in latency time
Time frame: 2 months
side effects
any side effects were recorded
Time frame: 2 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — it will be shared upon request
Supporting information: Study protocol
Ran from Mar 2024 to primary completion in Mar 2024, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.